retatrutide clinical trial obesity Eli Lilly infiltrates anti-obesity market as Phase III for begins Retatrutide: A Promising Option for

(PubMed) Northrop-Clewes CA, Thurnham DI

Brand Claims Notice: Certain marketing claims on the brand's website - including "America's #1 Rated," "Doctor-Approved," and claims about delivering ingredients "to your bloodstream" via transdermal delivery - are the brand's statements

However, over the next year, initiation slowed and even reversed: with first-time prescribing rates declining 31% by June 2025, reflecting an average month-over-month decrease of 0.004 percentage points

Try waiting 1 to 2 hours after a meal before working out

Ozempic and the Risk of nAMD A recent article in JAMA Ophthamology (June 2025) suggests that vascular changes triggered by GLP-1 activity may trigger or worsen nAMD in some patients, especially those who are older, diabetic, or already at risk for macular degeneration